• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

The Weekly Roundup: May 30-June 3

ICYMI, this week we had stories from the trending skin care from May, FDA's newest pipeline move, and more.

POLL: Do You Need More Resources on How to Work With Infusion Centers?

Melanoma Overdiagnosis: Awareness May Not Change Behavior

Dermatopathologists diagnose melanoma at similar rates regardless of whether they think the skin cancer is overdiagnosed.

Palliative Perspective: Aligning Melanoma Treatment with Patient Goals

There is room for improvement in dermatology palliative care; training can help providers raise that standard.

AAD Focused AK Update Recommends Topical Tirbanibulin

The AAD recently added topical tirbanibulin (Klisyri: Almirall) to its list of recommended therapies for treating AK.

Meet the Aesthetics Expert with Dr. Will Kirby: Ryan Greene, MD, PhD, FACS

In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Ryan Greene, MD, PhD, FACS, about how this board-certified facial plastic surgeon applies his expertise to non-surgical aesthetics and what that means for improving outcomes with injectables and other minimally invasive techniques.

FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis

Dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals, Inc) has received priority review for its supplemental Biologics License Application by the FDA to treat adult patients with prurigo nodularis.

TMB-001 Granted FDA Breakthrough Therapy Designation

Timber Pharmaceuticals has received an FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis.

The Mainstream Patient: May 31

This week's edition of the Mainstream Patients features stories about heat rash, drinking Aloe Vera juice, and more.

What's Trending in Skin Care: May 2022

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of May.

Think Globally to Combat Acne

Take a world tour of the global game-changing advances and home-grown success strategies dermatologists in the United States and abroad are using to tackle the challenges of acne.

When Peels Beat Lasers for Acne Scarring, Other Conditions

An expert takes a look at both modalities in treating acne scarring, wrinkles, pigmentation issues, and actinic keratoses.

Novel Triple-Combination Acne Treatment Shows Early, Significant Results

Investigators explore the effectiveness of new combination therapies to address the multifactorial pathophysiology of acne vulgaris.

How Well Can AI Diagnose and Monitor Acne?

Two new studies analyzes the competencies and limitations of teaching a neural network to recognize facial acne.

I Can’t Afford to Have a Chaperone With Me During Skin Exams: Can I Get Into Trouble?

In this month's Legal Eagle, David J. Goldberg, MD, JD, writes about the legal burden of having a chaperone during skin exams.

Hair Happenings

In this month's Cosmetic Conundrums, Zoe Diana Draelos, MD, tackles the issues of hair loss after pregnancy, the role of pH in hair care, hair strengthening conditioner, and more.

Protect Yourself From Risk With Strategies Beyond Insurance

Approximately 36% of all physicians will be sued at least once before they are aged 45 years.

Acne Update: 2022’s Top 5 Trends

Fresh spins on established treatments and newly FDA-approved drugs and devices provide a framework for changing therapies and modalities for acne regimens.

Sanofi Sells Rights of Cemiplimab to Regeneron

Regeneron Pharmaceuticals Inc came to an agreement to buy the drug from Sanofi for up to $1.1 billion.

A look inside the 2022 PA & NP Fall Clinical Dermatology Conference

Offering in-person and virtual formats, the 2022 PA & NP Fall Clinical Dermatology Conference includes 3 days of informative sessions designed to help health care practitioners “unlock their value to their patients and their practice.

2022 Conference Highlights How-to Strategies to Improve Clinical Outcomes and Practice Efficiency

Darrell S. Rigel highlights what to expect for the 2022 PA&NP Fall Clinical Conference happening June 3 to 5 in Scottsdale, Arizona.

Related Videos
3 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.